|
Predictive power of multimarker panels |
||||
| Panel |
Timepoint |
Response type |
Sensitivity (%) |
Specificity (%) |
|
|
||||
| α-Fetoprotein, soluble vascular cell adhesion molecule 1, MMP-9 |
Pretreatment |
Clinical complete response versus no response |
83 |
91 |
| Tissue plasminogen activator inhibitor 1 |
Pretreatment |
Clinical complete response/clinical partial response versus no response |
75 |
77 |
| MMP-3, luteinizing hormone, thyroid-stimulating hormone |
Pre-cycle 2 |
Clinical complete response versus no response |
82 |
73 |
| ErbB2, epidermal growth factor receptor, migration inhibitory factor, MMP-2, CD40 ligand |
Pre-cycle 2 |
Pathologic complete response/pathologic partial response versus no response |
85 |
69 |
Nolen et al. Breast Cancer Research 2008 10:R45 doi:10.1186/bcr2096 |
||||